Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus.
Tseng
A L
AL
Immunodeficiency Clinic, Toronto Hospital-Toronto General Division, Ontario, Canada.
Dolovich
L
L
Salit
I E
IE
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006312:Hearing Loss, Bilateral / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014012:Tinnitus / Q000139:chemically induced*; D014717:Vertigo / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D017963:Azithromycin